| HOME >> MEDICINE >> TECHNOLOGY |
Disposable Technologies for Manufacturing of Biologics
Managing Large Volume, Single Use Disposables
Optimization of Antibody Processing: Upstream and Downstream
Simulated Moving Bed Chromatography
Implementation of Membrane Technology in Antibody Large-Scale Purification
Development of Viral Clearance Strategies for Large-Scale Monoclonal Antibody Production
Downstream Processing: Removing Economic and Technical Bottlenecks
Purification of Monoclonal and Genetically Engineered Antibodies
Regulatory Environment for Follow-on Biologics
Post-Approval Changes for Large Scale Biopharmaceutical Manufacturing: Global
FDA and Regulatory Issues in Biopharmaceutical Manufacturing
Strategic Issues: Capital Investments
Pricing Issues for Biotechnology Products
Economics of Scheduling, De-bottlenecking, and Cycle Time
Intellectual Property Considerations in Scale-Up of Biomanufacturing Processes
Forecasting Industry-wide Biopharmaceutical Manufacturing Capacity Requirements
Worldwide Therapeutic Protein Production Capacity
Authors and Reviewers:
Accelsiors Group International
Advanced Scientifics Inc.
Amgen, Inc.
Amgen, Inc.
Amgen, Inc.
Amgen, Inc.
Amgen, Inc.
Biogen IDEC
Biomanufacturing Training and Education Center
BioPharm Services UK
BioProcess Technology
Biotechnology Unit, NIDDK, NIH
Bristol Myers Squibb
Chromos, Burnaby, BC
Cambrex Bio Science
Clonex Development, Inc.
Consultants Inc.
Eli Lilly & Co.
Eli Lilly & Co.
Eli Lilly & Co.
Eli Lilly & Co.
Falconridge Associates
Fluor Corporation/Fluor Daniel Inc.
Fluor Corporation/Fluor Daniel Inc.
Fluor Corporation/Fluor Daniel Inc.
| SOURCE Reportlinker Copyright©2010 PR Newswire. All rights reserved |